Výsledky vyhledávání - Ho Yeong Lim

Upřesnit hledání
  1. 1
    Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma

    Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma Autor Youngil Koh, Ho Yeong Lim, J.-H. Ahn, J. L. Lee, Sun Young Rha, Yoon Jun Kim, T. M. Kim, Seung‐Hoon Lee

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma

    Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma Autor Jeong Il Yu, Su Jin Lee, Jeeyun Lee, Ho Yeong Lim, Seung Woon Paik, Gyu Sang Yoo, Changhoon Choi, Hee Chul Park

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review

    Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review Autor Joon Oh Park, Do‐Youn Oh, Chiun Hsu, Jen‐Shi Chen, Li‐Tzong Chen, Mauro Orlando, Jong Seok Kim, Ho Yeong Lim

    Vydáno 2015
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

    Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma Autor Richard S. Finn, Yoon‐Koo Kang, Mary F. Mulcahy, Blasé N. Polite, Ho Yeong Lim, Ian Walters, Christine Baudelet, Demetrios Manekas, Joong‐Won Park

    Vydáno 2012
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival

    c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival Autor Su Jin Lee, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Young Suk Park, Seung Tae Kim

    Vydáno 2018
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma

    Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma Autor Changhoon Yoo, JiHoon Kang, Ho Yeong Lim, Jee Hyun Kim, Myung Ah Lee, Kyung-Hun Lee, Tae‐You Kim, Baek‐Yeol Ryoo

    Vydáno 2018
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study

    Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study Autor Jordi Bruix, Won Young Tak, Antonio Gasbarrini, Armando Santoro, M. Colombo, Ho-Yeong Lim, Vincenzo Mazzaferro, Reiner Wiest, María Reig, Thierry André, Luigi Bolondi

    Vydáno 2013
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    P21-Activated Kinase 4 Overexpression in Metastatic Gastric Cancer Patients

    P21-Activated Kinase 4 Overexpression in Metastatic Gastric Cancer Patients Autor Hee Kyung Ahn, Jiryeon Jang, Jeeyun Lee, Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Kyoung‐Mee Kim, Won Ki Kang

    Vydáno 2011
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Polymorphic markers associated with severe oxaliplatin‐induced, chronic peripheral neuropathy in colon cancer patients

    Polymorphic markers associated with severe oxaliplatin‐induced, chronic peripheral neuropathy in colon cancer patients Autor Hong‐Hee Won, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Jong‐Won Kim, Soo‐Youn Lee, Se Hoon Park

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Lung metastases in metastatic gastric cancer: pattern of lung metastases and clinical outcome

    Lung metastases in metastatic gastric cancer: pattern of lung metastases and clinical outcome Autor Jee Hyun Kong, Jeeyun Lee, Chin-A Yi, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Keon Woo Park, Won Ki Kang

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Impact of epidermal growth factor receptor (EGFR) kinase mutations, <i>EGFR</i> gene amplifications, and <i>KRAS</i> mutations on survival of pancreatic adenocarcinoma

    Impact of epidermal growth factor receptor (EGFR) kinase mutations, <i>EGFR</i> gene amplifications, and <i>KRAS</i> mutations on survival of pancreatic adenocarcinoma Autor Jeeyun Lee, Kee‐Taek Jang, Chang‐Seok Ki, Taekyu Lim, Young Suk Park, Ho Yeong Lim, Dongwook Choi, Won Ki Kang, Keunchil Park, Joon Oh Park

    Vydáno 2007
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy

    Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy Autor Seung Tae Kim, Samuel J. Klempner, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Kyoung-Mee Kim, Jeeyun Lee

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma

    Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma Autor Changhoon Yoo, Joong‐Won Park, Yoon Jun Kim, Do Young Kim, Su Jong Yu, Tae Seop Lim, Su Jin Lee, Baek‐Yeol Ryoo, Ho Yeong Lim

    Vydáno 2018
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma

    Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma Autor Chan Kim, Hannah Yang, Il Hwan Kim, Beodeul Kang, Hyeyeong Kim, Hyunho Kim, Won Suk Lee, Sanghoon Jung, Ho Yeong Lim, Jaekyung Cheon, Hong Jae Chon

    Vydáno 2022
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Whole-genome sequencing of matched primary and metastatic hepatocellular carcinomas

    Whole-genome sequencing of matched primary and metastatic hepatocellular carcinomas Autor Limei Ouyang, Jeeyun Lee, Cheol-Keun Park, Mao Mao, Yujian Shi, Zhuolin Gong, Hancheng Zheng, Yingrui Li, Yonggang Zhao, Guangbiao Wang, Huiling Fu, Jhingook Kim, Ho Yeong Lim

    Vydáno 2014
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia

    Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcino... Autor Shukui Qin, Yuxian Bai, Ho Yeong Lim, Sumitra Thongprasert, Yee Chao, Jia Fan, Tsai‐Shen Yang, Vajarabhongsa Bhudhisawasdi, Won Ki Kang, Yu Zhou, Jee Hyun Lee, Yan Sun

    Vydáno 2013
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma

    Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma Autor Thomas E. Hutson, Bernard Escudier, Emilio Esteban, Georg A. Bjarnason, Ho Yeong Lim, K. Pittman, P. Senico, Andreas G. Niethammer, Dongrui R. Lu, Hariharan Subramanian, Robert J. Motzer

    Vydáno 2013
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Temsirolimus vs Sorafenib As Second Line Therapy in Metastatic Renal Cell Carcinoma: Results from the Intorsect Trial

    Temsirolimus vs Sorafenib As Second Line Therapy in Metastatic Renal Cell Carcinoma: Results from the Intorsect Trial Autor Thomas E. Hutson, Bernard Escudier, E. Barrado, Georg A. Bjarnason, Ho Yeong Lim, K. Pittman, P. Senico, Andreas G. Niethammer, Dongrui R. Lu, Seetharaman Hariharan, Robert J. Motzer

    Vydáno 2012
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  19. 19
    Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer

    Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer Autor Jung Yong Hong, Ji Yeong An, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Kyoung‐Mee Kim, Won Ki Kang, Seung Tae Kim

    Vydáno 2020
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  20. 20
    Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours

    Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours Autor Hee Kyung Ahn, Joon Young Choi, K.-M. Kim, Hong Kwan Kim, Seong‐Ho Choi, Seong Ho Park, J. O. Park, Ho Yeong Lim, Wonseok Kang, J. Lee, Y. S. Park

    Vydáno 2013
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: